http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories
-
Frequency Therapeutics (FREQ) Reports Topline Phase 2b Data for FX-322
-
Frequency Therapeutics Announces Topline Results for its Phase 2b Study of FX-322 for the Treatment of Sensorineural Hearing Loss
-
Frequency Therapeutics Announces Formation of Clinical Advisory Board for Remyelination in Multiple Sclerosis Program
-
Frequency Therapeutics Announces First Patient Dosed in Phase 1b Study of FX-345, the Company’s Second Therapeutic Candidate for Sensorineural Hearing Loss
-
Frequency Therapeutics to Host Virtual Investor Event, Highlighting Hearing Restoration Candidate FX-322 in Advance of Q1 Clinical Results
-
Frequency Therapeutics Provides Business Updates and Third Quarter 2022 Financial Results
-
Frequency Therapeutics Completes Enrollment of Phase 2b Study of FX-322 for the Treatment of Sensorineural Hearing Loss
-
Frequency Therapeutics to Participate in September Investor and Medical Conferences
-
Frequency Therapeutics Provides Business Updates and Second Quarter 2022 Financial Results
-
Frequency Therapeutics to Participate in 2022 H.C. Wainwright Global Investment Conference
-
Frequency Therapeutics Provides Business Updates and First Quarter 2022 Financial Results
-
Frequency Therapeutics to Participate in B. Riley Securities’ Neuro & Ophthalmology Investor Conference
-
Frequency Therapeutics Provides Business Updates and Reports Fourth Quarter and Full Year 2021 Financial Results
-
Frequency Therapeutics to Participate in Upcoming March 2022 Investor Conferences
-
Frequency Therapeutics to Present 2022 Business and Pipeline Overview at the 40th Annual J.P. Morgan Healthcare Conference
-
Frequency Therapeutics (FREQ) Reports Results from FX-322-113 Severe Sensorineural Hearing Loss Study Showing Speech Perception Improvements in Noise
-
Frequency Therapeutics Shares Results from FX-322-113 Severe Sensorineural Hearing Loss Study Showing Speech Perception Improvements in Noise
-
Frequency Therapeutics Provides Business Updates and Third Quarter 2021 Financial Results
-
Frequency Therapeutics Holds Virtual R&D Event Highlighting Clinical Advancement of FX-322, a New Potential Restorative Treatment for Hearing Loss and In Vivo Data for Its Remyelination Program in
-
Frequency Therapeutics Virtual R&D Event to Detail FX-322 Clinical Advances, a New Program for Hearing Restoration and In Vivo Data from its MS Remyelination Program
-
Frequency Therapeutics Announces First Subject Dosed in FX-322 Phase 2b Acquired Sensorineural Hearing Loss (SNHL) Study and FDA Agreement on Speech Perception as Primary Endpoint
-
Frequency Therapeutics (FREQ) New FX-322 Data Shows Additional Study Participants Gain Hearing Improvements at Later Time Points
-
Frequency Therapeutics Announces New FX-322 Results Showing That Additional Study Participants Gain Hearing Improvements at Later Time Points
-
Frequency Therapeutics to Present at Upcoming Investor Conferences
-
Frequency Therapeutics Provides Business Updates and Second Quarter 2021 Financial Results
-
Frequency Therapeutics to Present at Upcoming Jefferies and Goldman Sachs Healthcare Investor Conferences
-
Frequency Therapeutics Provides Statement of Support for the Hearing Loss Association of America’s Externally-Led Patient-Focused Drug Development Meeting to Address Sensorineural Hearing Loss
-
Frequency Therapeutics Provides Business Updates and Reports First Quarter 2021 Financial Results
-
Frequency Therapeutics Expands its Clinical Development Team, Adding Expertise in Inner Ear Physiology and Translational Science
-
Frequency Therapeutics to Present at the 20th Annual Needham Virtual Healthcare Conference
-
Frequency Therapeutics Provides Business Updates and Reports Fourth Quarter and Full Year 2020 Financial Results
-
Frequency Therapeutics (FREQ) Releases New Data from Two FX-322 Clinical Studies; Plans to Advance Single-Dose Regimen
-
Frequency Therapeutics Releases New Data from Two FX-322 Clinical Studies; Plans to Advance Single-Dose Regimen
-
Frequency Therapeutics (FREQ) Reports Publication of Phase 1/2 Data Showing Hearing Improvements in Acquired Sensorineural Hearing Loss Patients Receiving FX-322
-
Frequency Therapeutics Announces Publication of Phase 1/2 Data Showing Hearing Improvements in Acquired Sensorineural Hearing Loss Patients Receiving FX-322
-
Frequency Therapeutics Appoints Kevin Franck, Ph.D., as Senior Vice President, Strategic Marketing and New Product Planning
-
Frequency Therapeutics Appoints Quentin McCubbin, Ph.D., as Chief Manufacturing Officer
-
Frequency Therapeutics to Present 2021 Business and Pipeline Overview at the 39th Annual J.P. Morgan Healthcare Conference
-
Frequency Therapeutics to Host Investor Event on the Potential for Restorative Treatments for Acquired Sensorineural Hearing Loss
-
Frequency Therapeutics Appoints Peter Pfreundschuh as Chief Financial Officer
-
Frequency Therapeutics Provides Business Updates and Reports Third Quarter 2020 Financial Results
-
Frequency Therapeutics Announces Expanded FX-322 Clinical Development Program and Upcoming Day-90 Phase 2a Analysis
-
Frequency Therapeutics (FREQ) Names Cynthia Feldmann to Board
-
Frequency Therapeutics Appoints Cynthia Feldmann to its Board of Directors
-
Frequency Therapeutics (FREQ) Reports Complete Enrollment of FX-322 Phase 2a Study for Sensorineural Hearing Loss
-
Frequency Therapeutics Completes Enrollment of FX-322 Phase 2a Study for Sensorineural Hearing Loss
-
Frequency Therapeutics Presents Results Demonstrating Sustained Improvement in Hearing Loss Patients Treated with FX-322
-
Frequency Therapeutics to Present at Upcoming Investor Conferences and Medical Meetings
-
Frequency Therapeutics Provides Business Updates and Reports Second Quarter 2020 Financial Results
-
Frequency Therapeutics to Present at Upcoming Investor Conferences
